tofacitinib
pfizer
['tofa', 'tofacitinib']
across extended mace endpoints risk was numerically higher with tofacitinib vs tnfi in pts with a history of artherosclerotic cv disease (ascvd). cv risk (mace-8 with hf +vte) was higher in the tofa 10mg bd vs tnfi. buch m #l06 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach